Apoe gene polymorphisms and response to statin therapy

ABSTRACT Published studies investigating the role of _APOE_ gene on lipid response (total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol

(HDL-C) and triglycerides) to statin treatment have reported inconsistent results. A meta-analysis was conducted to estimate the lipid response to statin treatment among _APOE_ genetic

variants (e2 carriers, e3e3 homozygotes and e4 carriers). Twenty-four studies were included in the meta-analyses. The pooled mean reduction (Δ_μ_) in TC from baseline was significant for all

variants (e2 carriers: Δ_μ_=−27.7% (−32.5 to −22.8%), e3e3: Δ_μ_=−25.3% (−28.0 to −22.6%) and e4 carriers: Δ_μ_=−25.1% (−29.3 to −21.0%)). Significant changes in LDL-C, HDL-C and

triglyceride levels were also noted for all genotypes, although these changes did not differ significantly among genotypic groups. There was significant heterogeneity among the studies.

Given these non-significant effects of _APOE_ genotypes on lipid responses, there is little reason to consider the use of _APOE_ genetic testing for guiding treatment with statins. Access

through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal

Receive 6 print issues and online access $259.00 per year only $43.17 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may

be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support

SIMILAR CONTENT BEING VIEWED BY OTHERS ASSOCIATION BETWEEN THE _ABCA1_ (R219K) POLYMORPHISM AND LIPID PROFILES: A META-ANALYSIS Article Open access 05 November 2021 NOVEL AND FUTURE

LIPID-MODULATING THERAPIES FOR THE PREVENTION OF CARDIOVASCULAR DISEASE Article 13 April 2023 ENDOTHELIAL CELL-RELATED GENETIC VARIANTS IDENTIFY LDL CHOLESTEROL-SENSITIVE INDIVIDUALS WHO

DERIVE GREATER BENEFIT FROM AGGRESSIVE LIPID LOWERING Article 26 February 2025 ACCESSION CODES ACCESSIONS GENBANK/EMBL/DDBJ * rs7412 and rs429358 ABBREVIATIONS * HDL-C: high-density

lipoprotein cholesterol * LDL-C: low-density lipoprotein cholesterol * TC: total cholesterol REFERENCES * Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C _et al_. Efficacy

and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. _Lancet_ 2005; 366: 1267–1278. Article  CAS 

Google Scholar  * Kajinami K, Takekoshi N, Brousseau ME, Schaefer EJ . Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of

coronary heart disease management. _Atherosclerosis_ 2004; 177: 219–234. Article  CAS  PubMed  Google Scholar  * Mangravite LM, Thorn CF, Krauss RM . Clinical implications of

pharmacogenomics of statin treatment. _Pharmacogenomics J_ 2006; 6: 360–374. Article  CAS  PubMed  Google Scholar  * Maitland-van der Zee AH, Klungel OH, Stricker BH, Monique Verschuren WM,

Kastelein JJ, Leufkens HG _et al_. Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors. _Atherosclerosis_ 2002; 163: 213–222. Article  CAS  PubMed  Google Scholar

  * Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC . Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. _Am J Epidemiol_ 2002; 155: 487–495.

Article  PubMed  Google Scholar  * Song Y, Stampfer MJ, Liu S . Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. _Ann Intern Med_ 2004; 141: 137–147. Article 

PubMed  Google Scholar  * Ballantyne CM, Herd JA, Stein EA, Ferlic LL, Dunn JK, Gotto Jr AM _et al_. Apolipoprotein E genotypes and response of plasma lipids and progression-regression of

coronary atherosclerosis to lipid-lowering drug therapy. _J Am Coll Cardiol_ 2000; 36: 1572–1578. Article  CAS  PubMed  Google Scholar  * Carmena R, Roederer G, Mailloux H, Lussier-Cacan S,

Davignon J . The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism. _Metabolism_ 1993; 42: 895–901.

Article  CAS  PubMed  Google Scholar  * Christidis DS, Liberopoulos EN, Kakafika AI, Miltiadous GA, Cariolou M, Ganotakis ES _et al_. The effect of apolipoprotein E polymorphism on the

response to lipid-lowering treatment with atorvastatin or fenofibrate. _J Cardiovasc Pharmacol Ther_ 2006; 11: 211–221. Article  CAS  PubMed  Google Scholar  * De Knijff P, Stalenhoef AF,

Mol MJ, Gevers Leuven JA, Smit J, Erkelens DW _et al_. Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia.

_Atherosclerosis_ 1990; 83: 89–97. Article  CAS  PubMed  Google Scholar  * Fiegenbaum M, da Silveira FR, Van der Sand CR, Van der Sand LC, Ferreira ME, Pires RC _et al_. Pharmacogenetic

study of apolipoprotein E, cholesteryl ester transfer protein and hepatic lipase genes and simvastatin therapy in Brazilian subjects. _Clin Chim Acta_ 2005; 362: 182–188. Article  CAS 

PubMed  Google Scholar  * Kobayashi T, Homma Y . Effects of low-dose pravastatin on plasma levels of lipids and apolipoproteins in Japanese type II hyperlipoproteinemic subjects with

apolipoprotein E phenotype E3/2, E3/3, and E4/3. _J Clin Pharmacol_ 2001; 41: 1055–1058. Article  CAS  PubMed  Google Scholar  * Korhonen T, Hannuksela ML, Seppanen S, Kervinen K, Kesäniemi

YA, Savolainen MJ . The effect of the apolipoprotein E phenotype on cholesteryl ester transfer protein activity, plasma lipids and apolipoprotein A I levels in hypercholesterolaemic patients

on colestipol and lovastatin treatment. _Eur J Clin Pharmacol_ 1999; 54: 903–910. Article  CAS  PubMed  Google Scholar  * Maitland-van der Zee AH, Jukema JW, Zwinderman AH, Hallman DM, De

Boer A, Kastelein JJ _et al_. Apolipoprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS). _Acta Cardiol_ 2006; 61: 327–331. Article  PubMed 

Google Scholar  * O’Malley JP, Illingworth DR . The influence of apolipoprotein E phenotype on the response to lovastatin therapy in patients with heterozygous familial hypercholesterolemia.

_Metabolism_ 1990; 39: 150–154. Article  PubMed  Google Scholar  * Ojala JP, Helve E, Ehnholm C, Aalto-Setälä K, Kontula KK, Tikkanen MJ _et al_. Effect of apolipoprotein E polymorphism and

XbaI polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia. _J Intern Med_ 1991; 230: 397–405. Article  CAS  PubMed  Google

Scholar  * Ordovas JM, Lopez-Miranda J, Perez-Jimenez F, Rodriguez C, Park JS, Cole T _et al_. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG

CoA reductase inhibitor therapy. _Atherosclerosis_ 1995; 113: 157–166. Article  CAS  PubMed  Google Scholar  * Peña R, Lahoz C, Mostaza JM, Jiménez J, Subirats E, Pintó X, Taboada M,

López-Pastor A, Rap Study Group. Effect of apoE genotype on the hypolipidaemic response to pravastatin in an outpatient setting. _J Intern Med_ 2002; 251: 518–525. Article  PubMed  Google

Scholar  * Rustemeijer C, Schouten JA, Voerman HJ, Beynen AC, Donker AJ, Heine RJ . Is pseudocholinesterase activity related to markers of triacylglycerol synthesis in Type II diabetes

mellitus? _Clin Sci (Lond)_ 2001; 101: 29–35. Article  CAS  Google Scholar  * Tavintharan S, Lim SC, Chan YH, Sum CF . Apolipoprotein E genotype affects the response to lipid-lowering

therapy in Chinese patients with type 2 diabetes mellitus. _Diabetes Obes Metab_ 2007; 9: 81–86. Article  CAS  PubMed  Google Scholar  * Watanabe J, Kobayashi K, Umeda F, Yamauchi T, Mimura

K, Nakashima N _et al_. Apolipoprotein E polymorphism affects the response to pravastatin on plasma apolipoproteins in diabetic patients. _Diabetes Res Clin Pract_ 1993; 20: 21–27. Article 

CAS  PubMed  Google Scholar  * Ye P, Shang Y, Ding X . The influence of apolipoprotein B and E gene polymorphisms on the response to simvastatin therapy in patients with hyperlipidemia.

_Chin Med Sci J_ 2003; 18: 9–13. CAS  PubMed  Google Scholar  * Zuccaro P, Mombelli G, Calabresi L, Baldassarre D, Palmi I, Sirtori CR . Tolerability of statins is not linked to CYP450

polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. _Pharmacol Res_ 2007; 55: 310–317. Article  CAS  PubMed  Google Scholar  *

Pedro-Botet J, Schaefer EJ, Bakker-Arkema RG, Black DM, Stein EM, Corella D _et al_. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner.

_Atherosclerosis_ 2001; 158: 183–193. Article  CAS  PubMed  Google Scholar  * Sanllehy C, Casals E, Rodriguez-Villar C, Zambon D, Ojuel J, Ballesta AM, Ros E . Lack of interaction of

apoliprotein E phenotype with the lipoprotein response to lovastoctin or gemtibrozil in patients with primary hypercholesterolemia. _Metabolism_ 1998; 47: 560–565. Article  CAS  PubMed 

Google Scholar  * Donnelly LA, Palmer CN, Whitley AL, Lang CC, Doney AS, Morris AD, Donnan PT . Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in

diabetes: a GO-DARTS study. _Pharmaco Gen_ 2008; 18: 279–287. Article  CAS  Google Scholar  * Thompson JF, Man M, Johnson KJ, Wood LS, Lira ME, Lloyd DB _et al_. An association study of 43

SNPs in 16 candidate genes with atorvastatin response. _Pharmacogenomics J_ 2005; 5: 352–358. Article  CAS  PubMed  Google Scholar  * Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton

Jr VP, Ridker PM . Pharmacogenetic study of statin therapy and cholesterol reduction. _JAMA_ 2004; 291: 2821–2827. Article  CAS  PubMed  Google Scholar  * Trikalinos TA, Salanti G, Zintzaras

E, Ioannidis JP . Meta-analysis methods. _Adv Genet_ 2008; 60: 311–334. Article  PubMed  Google Scholar  * Zintzaras E, Lau J . Synthesis of genetic association studies for pertinent

gene-disease associations requires appropriate methodological and statistical approaches. _J Clin Epidemiol_ 2008; 61: 634–645. Article  PubMed  Google Scholar  * Ioannidis JP, Ntzani EE,

Trikalinos TA, Contopoulos-Ioannidis DG . Replication validity of genetic association studies. _Nat Genet_ 2001; 29: 306–309. Article  CAS  PubMed  Google Scholar  * Roberts WC . The rule of

5 and the rule of 7 in lipid-lowering by statin drugs. _Am J Cardiol_ 1997; 80: 106–107. Article  CAS  PubMed  Google Scholar  * SEARCH Collaborative Group, Link E, Parish S, Armitage J,

Bowman L, Heath S, Matsuda F _et al_. SLCO1B1 variants and statin-induced myopathy--a genomewide study. _N Engl J Med_ 2008; 359: 789–799. Article  Google Scholar  * Ballantyne CM, Herd JA,

Stein EA, Ferlic LL, Dunn JK, Gotto Jr AM _et al_. Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug

therapy. _J Am Coll Cardiol_ 2000; 36: 1572–1578. Article  CAS  PubMed  Google Scholar  * Gerdes LU, Gerdes C, Kervinen K, Savolainen M, Klausen IC, Hansen PS _et al_. The apolipoprotein

epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction : a substudy of the Scandinavian simvastatin survival study.

_Circulation_ 2000; 101: 1366–1371. Article  CAS  PubMed  Google Scholar  * Maitland-van der Zee AH, Stricker BH, Klungel OH, Kastelein JJ, Hofman A, Witteman JC _et al_. The effectiveness

of hydroxy-methylglutaryl coenzyme A reductase inhibitors (statins) in the elderly is not influenced by apolipoprotein E genotype. _Pharmacogenetics_ 2002; 12: 647–653. Article  CAS  PubMed

  Google Scholar  * DerSimonian R, Laird N . Meta-analysis in clinical trials. _Control Clin Trials_ 1986; 7: 177–188. Article  CAS  PubMed  Google Scholar  * Zintzaras E . C677T and A1298C

methylenetetrahydrofolate reductase gene polymorphisms in schizophrenia, bipolar disorder and depression: a meta-analysis of genetic association studies. _Psychiatr Genet_ 2006; 16: 105–115.

Article  PubMed  Google Scholar  * Zintzaras E . Association of methylenetetrahydrofolate reductase (MTHFR) polymorphisms with genetic susceptibility to gastric cancer: a meta-analysis. _J

Hum Genet_ 2006; 51: 618–624. Article  CAS  PubMed  Google Scholar  * Zintzaras E, Raman G, Kitsios G, Lau J . Angiotensin-converting enzyme insertion/deletion gene polymorphic variant as a

marker of coronary artery disease: a meta-analysis. _Arch Intern Med_ 2008; 168: 1077–1089. Article  PubMed  Google Scholar  * Sterne JA, Egger M . Funnel plots for detecting bias in

meta-analysis: guidelines on choice of axis. _J Clin Epidemiol_ 2001; 54: 1046–1055. Article  CAS  PubMed  Google Scholar  * Begg CB, Mazumdar M . Operating characteristics of a rank

correlation test for publication bias. _Biometrics_ 1994; 50: 1088–1101. Article  CAS  PubMed  Google Scholar  Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of

Biomathematics, University of Thessaly School of Medicine, Larissa, Greece E Zintzaras, G D Kitsios & F Triposkiadis * Center for Clinical Evidence Synthesis, Institute for Clinical

Research and Health Policy Studies, Tufts Medical Center, Tufts University School of Medicine, Boston, MA, USA E Zintzaras, G D Kitsios, J Lau & G Raman Authors * E Zintzaras View author

publications You can also search for this author inPubMed Google Scholar * G D Kitsios View author publications You can also search for this author inPubMed Google Scholar * F Triposkiadis

View author publications You can also search for this author inPubMed Google Scholar * J Lau View author publications You can also search for this author inPubMed Google Scholar * G Raman

View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to E Zintzaras. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT

THIS ARTICLE CITE THIS ARTICLE Zintzaras, E., Kitsios, G., Triposkiadis, F. _et al._ _APOE_ gene polymorphisms and response to statin therapy. _Pharmacogenomics J_ 9, 248–257 (2009).

https://doi.org/10.1038/tpj.2009.25 Download citation * Received: 06 February 2009 * Revised: 28 April 2009 * Accepted: 05 May 2009 * Published: 16 June 2009 * Issue Date: August 2009 * DOI:

https://doi.org/10.1038/tpj.2009.25 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not

currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative KEYWORDS * statin * lipid * cholesterol * _APOE_ * polymorphism *

meta-analysis